List All Sarcoma Trials


NY-ESO-1 Specific T Cells After Cyclophosphamide for Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (2720)
A Study To Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/ Round Cell Liposarcoma using Autologous NY-ESO-1 Specific CD8+ T Cells with Cyclophosphamide Pre-Conditioning but Without the Use of IL-2
Status Conditions Phase Study ID
Recruiting Sarcoma Phase I 2720

This phase I trial studies the side effects and best way to give NY-ESO-1 specific T cells after cyclophosphamide in treating patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. Placing a gene that has been created in the laboratory into white blood cells may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving NY-ESO-1 specific T cells with cyclophosphamide may kill more tumor cells.

Seth Pollack
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Histopathological documentation of sarcoma
  • Pulse > 45 or < 120
  • Weight >= 45 kg
  • Temperature =< 38 Celsius (C) (=< 100.4 Fahrenheit [F])
  • White blood cell (WBC) >= 2,000
  • Hematocrit (HCT) >= 30%
  • Platelets >= 75,000
  • A diagnosis of synovial sarcoma and myxoid/ round cell liposarcoma
  • Patients must have "advanced disease"; usually, this will mean metastatic disease; this may also be multiply recurrent disease or locally advanced disease; locally advanced disease is defined for this study as disease where a mutilating surgery is required and the patient is more likely than not to die of their disease despite an aggressive operation; patients with metastatic disease that has been resected or radiated are allowed to participate; Response Evaluation Criteria in Solid Tumors (RECIST) evaluable disease is not necessary for participation
  • NY-ESO-1 positive by immunohistochemistry (IHC) (for this study, even a small level of positivity is acceptable); for patients with < 5% NY-ESO-1 by IHC positivity, the level of staining should be discussed with the patient and they should be informed that this will likely effect the efficacy of the therapy; this conversation must be documented in the patient's medical chart
  • Human leukocyte antigen (HLA)-A0201 or HLA-A2402
  • Zubrod performance status of '0-1'
  • All patients must have an electrocardiogram (ECG) within 2 weeks of starting conditioning
  • All patients must have a stress test within 6 months of starting treatment showing no evidence of cardiac ischemia
  • All patients must have an echo or multi gated acquisition scan (MUGA) scan showing ejection fraction (EF) > 50% and normal troponin and creatine kinase (CK) myoglobin binding (MB) (echo may be done at the time of stress test as a stress echo); if the patient has received cardiotoxic chemotherapy such as Adriamycin, they must have had an echo or MUGA scan since completing this treatment
  • If there is a patient with an NY-ESO-1 expressing soft tissue sarcoma who would be otherwise eligible for the trial, which is either not synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCL) or there is controversy about the diagnosis, eligibility will be decided by the principal investigator (PI)
  • Patients must have NY-ESO-1 specific cells already produced or in production; these cells may be either in the process of their final expansion (for fresh infusion) or expanded and frozen at the time of enrollment

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)
  • Patients for whom we are unable to generate NY-ESO-1 specific cells
  • Pregnant women, nursing women, and men and women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to study entry
  • Serum creatinine > 1.6 mg/dL or glomerular filtration rate < 50
  • Serum glutamic oxaloacetic transaminase (SGOT) > 150 IU or > 3x upper limit of normal
  • Bilirubin > 1.6 mg/dL
  • Prothrombin time > 1.5 x control
  • Active symptomatic congestive heart failure
  • Clinically significant hypotension
  • Newly diagnosed cardiac arrhythmia; patients with an arrhythmia that has been stable for at least 6 months will be allowed to participate
  • Untreated central nervous system (CNS) metastasis; patients with CNS metastasis will be allowed on study once treated
  • Patients with systemic infections requiring antibiotics or chronic maintenance/ suppressive therapy; once the infection in question has resolved, patients may participate
  • Systemic anticancer treatments (including chemotherapy and biologics) less than 3 weeks prior to T cell therapy; locally directed therapy (e.g. radiation) 2 weeks prior to cell infusion
  • Clinically significant autoimmune disorders requiring systemic immunosuppression for control
  • Patients who are known to be human immunodeficiency virus (HIV) positive are not eligible for this study
  • Current treatment with steroids
  • Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); (if a patient was not tested at the time of their leukapheresis, they must be tested prior to receiving T cell infusion; if testing was done for leukapheresis, this is adequate)
  • Patients with a history of proven myocarditis, pericarditis, and/ or endocarditis
  • Patients who do not meet the screening inclusion criteria will not be leukapheresed
Last Updated
August 12, 2014
See this trial at
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.